IPO registrations (S-1, F-1) · Registrants
Ablynx NV
- SEC CIK
- 1617582 · filings on EDGAR ↗
- Registration
- Form F-1, first filed 2017-10-02, last 2017-10-24; 1 initial registration, 5 amendments
- Outcome
- Final prospectus filed 2017-10-25; declared effective 2017-10-24
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- C9
- Business address
- TECHNOLOGIEPARK 21, ZWIJNAARDE, Ghent, C9 9052
- EDGAR entity type
- other
Offering terms
- Final price
- $17.50 per ADS (424B4 filed 2017-10-25)
- Shares sold
- 11,430,000
- Gross proceeds
- $200,025,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ABLX
- Lead underwriters
- Merrill Lynch; J.P. Morgan (4,000,500 shares); Jefferies (2,000,250 shares)
- Syndicate
- The ADSs; BofA Securities; Baird (685,800); Bryan, Garnier & Co (171,450); Ladenburg Thalmann (571,500); ADSs Merrill Lynch, Pierce, Fenner & Smith Incorporated (4,000,500)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
Filings 9
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-10-02 | F-1 | F-1 (foreign registration) | Ablynx NV | 0001193125-17-301060 ↗ |
| 2017-10-13 | F-1/A | F-1/A (amendment) | Ablynx NV | 0001193125-17-309113 ↗ |
| 2017-10-17 | F-1/A | F-1/A (amendment) | Ablynx NV | 0001193125-17-311335 ↗ |
| 2017-10-20 | F-1/A | F-1/A (amendment) | Ablynx NV | 0001193125-17-314728 ↗ |
| 2017-10-20 | F-1/A | F-1/A (amendment) | Ablynx NV | 0001193125-17-315472 ↗ |
| 2017-10-24 | F-1/A | F-1/A (amendment) | Ablynx NV | 0001193125-17-317497 ↗ |
| 2017-10-24 | EFFECT | EFFECT (declared effective) | Ablynx NV | 9999999995-17-002772 ↗ |
| 2017-10-25 | F-1MEF | F-1MEF (added securities) | Ablynx NV | 0001193125-17-318389 ↗ |
| 2017-10-25 | 424B4 | 424B4 (final prospectus) | Ablynx NV | 0001193125-17-318414 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-10-24 | F-1/A | registration statement | 9,464,575 | - | Nasdaq ABLX | 3 | primary document; shares headline | document ↗ | ||
| 2017-10-25 | 424B4 | final prospectus | $17.50 | 11,430,000 | $200,025,000 | Nasdaq ABLX | 9 | primary document; price sentence, shares headline, proceeds table, underwriting table 6, cover names 7 | document ↗ |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), C9 first:
- BioNTech SE 2M
- Immatics N.V. 2M
- CHEMOKINE THERAPEUTICS CORP A1
- Fusion Pharmaceuticals Inc. A6
- CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. AZ
- GENETIC TECHNOLOGIES LTD C3
- MESOBLAST LTD C3
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
In other datasets, the same topic (Health) in C9:
- Form D issuer: MDxHealth SA (Form D private offerings)
Interests: Biological Products, (No Diagnostic Substances) · Health